| Basics |
Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications.
|
| IPO Date: |
March 3, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.77B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.40 | 2.83%
|
| Avg Daily Range (30 D): |
$0.52 | 3.26%
|
| Avg Daily Range (90 D): |
$0.42 | 2.71%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.61M |
| Avg Daily Volume (30 D): |
2.81M |
| Avg Daily Volume (90 D): |
2.36M |
| Trade Size |
| Avg Trade Size (Sh.): |
87 |
| Avg Trade Size (Sh.) (30 D): |
84 |
| Avg Trade Size (Sh.) (90 D): |
86 |
| Institutional Trades |
| Total Inst.Trades: |
3,184 |
| Avg Inst. Trade: |
$2.29M |
| Avg Inst. Trade (30 D): |
$1.94M |
| Avg Inst. Trade (90 D): |
$2.23M |
| Avg Inst. Trade Volume: |
.13M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.91M |
| Avg Closing Trade (30 D): |
$3.71M |
| Avg Closing Trade (90 D): |
$3.83M |
| Avg Closing Volume: |
165.76K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-.7
|
$-.83
|
|
Diluted EPS
|
|
$-.7
|
$-.83
|
|
Revenue
|
$
|
$ 45.87M
|
$ 37.96M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -60.72M
|
$ -71.85M
|
|
Operating Income / Loss
|
$
|
$ -57.43M
|
$ -69.35M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ 8.17M
|
$ -45.36M
|
|
PE Ratio
|
|
|
|
|
|
|
